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provided the original work is properly cited.Cancer pain remains a major challenge and there is an urgent demand for the
development of specific mechanism-based therapies. Various diseases are
associated with unique signatures of expression of microRNAs (miRNAs), which
reveal deep insights into disease pathology. Using a comprehensive approach
combining genome-wide miRNA screening, molecular and in silico analyses with
behavioural approaches in a clinically relevant model of metastatic bone-cancer
pain inmice, we now show that tumour-induced conditions are associated with a
marked dysregulation of 57miRNAs in sensory neurons corresponding to tumour-
affected areas. By establishing protocols for interference with disease-induced
miRNA dysregulation in peripheral sensory neurons in vivo, we functionally
validate six dysregulated miRNAs as significant modulators of tumour-associated
hypersensitivity. In silico analyses revealed that their predicted targets include key
pain-related genes andwe identified Clcn3, a gene encoding a chloride channel, as
a key miRNA target in sensory neurons, which is functionally important in
tumour-induced nociceptive hypersensitivity in vivo. Our results provide new
insights into endogenous gene regulatorymechanisms in cancer pain and open up
attractive and viable therapeutic options.INTRODUCTION
Various forms of cancer are associated with debilitating pain.
Approximately one‐third of adults who are actively receiving
treatment for cancer and two‐thirds of those with advanced
malignant disease experience pain. Various types of carcinomas
and sarcomas metastasize to skeletal bones and cause
spontaneous bone pain, hyperalgesia (exaggerated pain) and
allodynia (pain in response to a normally innocuous stimulus),
which is accompanied by bone degradation and remodelling ofacology, Heidelberg
n Molecular Biology
CSB), University of
e, Esch-sur-Alzette,
, Germany
49 6221 548549;
Ltd on behalf of EMBO. Th
hich permits use, distributperipheral nerves (Mantyh, 2004; Wacnik et al, 2001). In a large
number of clinical cases, cancer‐associated pain, particularly the
neuropathic component thereof, is resistant to conventional
therapeutics or their application is severely limited owing to the
widespread side effects (Mantyh, 2006; Portenoy, 1999). In order
to develop novel, mechanism‐based therapeutic strategies, it is
imperative to delineate the cellular and molecular mechanisms
underlying cancer‐induced pain. Indeed, although tumour‐
induced pain shares features of inﬂammatory as well as
neuropathic pain, it is clearly distinguished by distinct
pathophysiological and mechanistic aspects (Mantyh, 2004;
Wacnik et al, 2001).
Non‐coding RNAs (ncRNAs), including the more well‐studied
microRNAs (miRNAs), are emerging as critical modulators of
normal cellular functions as well as pathological processes
(Huttenhofer & Schattner, 2006; Huttenhofer et al, 2005;
Mattick, 2004). Various diseases are associated with unique
miRNA expression signatures, which can not only be exploited
as diagnostic and prognostic markers, but also reveal deep
insights into disease pathology. Moreover, miRNAs can act asis is an open access article under
ion and reproduction in any medium,
EMBO Mol Med (2013) 5, 1740–1758
Research Articlewww.embomolmed.org
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diverse proteins and orchestrate multiple cellular pathways,
thereby harbouring tremendous therapeutic potential.
Recently, neuropathic pain conditions have been suggested to
deregulate the expression of miRNAs in pain pathways in
proﬁling studies (Aldrich et al, 2009; Bai et al, 2007; Imai
et al, 2011; Kusuda et al, 2011; Poh et al, 2011; von Schack
et al, 2011). Moreover, speciﬁc miRNAs have been associated
with inﬂammatory pain and the deregulation of ion channel
expression in sensory neurons in rodent models of inﬂammatory
and neuropathic pain (Favereaux et al, 2011; Li et al, 2011; Zhao
et al, 2010). However, to date, nothing has been reported on the
modulation of miRNA expression in conjunction with cancer
pain. Moreover, previous studies onmiRNA deregulation in pain
have mostly remained at the niveau of proﬁling expression; in
contrast, the functional consequences of miRNA deregulation,
their downstream targets and themechanisms bywhichmiRNAs
regulate processes modulating nociception have not been
resolved.
Both peripheral as well as spinal contributions are of critical
importance in understanding cancer pain and developing
therapeutic approaches (Gordon‐Williams & Dickenson, 2007;
Mantyh, 2004). Our key interest is to address plasticity
mechanisms at the interface between tumour cells and
nociceptive pathway; thereby, mechanisms operational in
sensory neurons are of prime interest. This is supported by
numerous studies, which have demonstrated changes in the
structure as well as the function of sensory neurons in cancer
pain states, which are attributed to effects of tumour growth and
tumour‐associated mediators (Cain et al, 2001; Constantin
et al, 2008; Mantyh, 2004).
Starting with a genome‐wide screen for miRNAs regulated in
sensory neurons of the dorsal root ganglia (DRG) in the state
of bone‐metastatic pain, we functionally validated a set of
prominently regulated miRNAs and report the impact of
deregulating their expression in sensory neurons on cancer‐
associated nociceptive hypersensitivity. Our in silico analysis of
gene targets of prominently regulated miRNAs not only revealed
that several prominent genes encoding known nociceptive
mediators, but also uncovered a novel target encoding a chloride
channel, which we functionally validated as an important
modulator of nociceptive sensitivity. Our results underscore
the importance of miRNA regulation in sensory neurons in
the context of bone metastatic pain and systematically delineate
the potential of ncRNAs as druggable targets for future treatment
of cancer‐associated pain.RESULTS
Genome‐wide identiﬁcation ofmiRNAs aberrantly expressed in
sensory neurons in the context of bone metastatic pain
Several types of carcinomas and sarcomas metastasize to the
bone and bone metastatic pain is the most common form of
cancer‐related pain (Mantyh, 2006). We therefore used a
previously described model of bone metastatic pain based upon
unilateral implantation of osteolytic ﬁbrosarcoma cells in theEMBO Mol Med (2013) 5, 1740–1758 calcaneous bone of paw heel. As we and others have reported
previously (Cain et al, 2001; Schweizerhof et al, 2009; Wacnik
et al, 2001), tumour growth was associated with the well‐
described triad of osteolytic tumour spread in the paw tissue,
structural changes in sensory nerves, such as hypertrophy and
sprouting, and development of intense mechanical hyper-
sensitivity to plantar stimulation of the paw (Schweizerhof
et al, 2009). Because tumour cells are known to secrete
mediators, which remodel and sensitize sensory neurons of
the corresponding DRG mostly L3‐L4 in mouse (Rigaud
et al, 2008), we addressed how the miRNA repertoire in
L3‐L4 DRGs changes following peripheral tumour induction.
In contrast to sham‐treated mice (saline injection in the
calcaneous bone), tumour‐bearing mice demonstrated exagger-
ated sensitivity and aversive withdrawal responses to very low,
normally innocuous intensities of mechanical force (e.g. 0.07 g).
This mechanical hypersensitivity started to become apparent on
post‐implantation Day 5 (PID‐5; p¼ 0.003) and gradually
increased over the time course (p¼ 0.011 on PID‐6, <0.001
from PID‐6 through 15, one‐way repeated measures ANOVA
followed by Student–Newman–Keuls post hoc test). Tumour‐
induced mechanical hypersensitivity was also apparent upon
comparing the 50% response threshold (Fig 1B; p< 0.01 as
compared to corresponding sham control and denotes †p< 0.01
as compared to corresponding basal value, two‐way ANOVA of
repeated measures followed by Bonferroni’s multiple compar-
isons post hoc test).
Selecting two different time points after tumour cell
implantation, i.e. PID‐4, when hypersensitivity is just starting
to evolve, and PID‐8, when signiﬁcant tumour‐mediated
hyperalgesia is established, we performed a genome‐wide
miRNA screen to detect tumour‐induced regulation of miRNAs
in L3‐L4 DRGs. Total RNA was processed and analysed using
Illumina miRNA expression arrays pre‐spotted with 655 mature
miRNAs according to the miRBase version 12.0. Following
quantile array normalization to correct for systematic differences
between arrays, which do not represent biological variation of
interest between experimental groups (Bolstad et al, 2003;
Chudin et al, 2006), mean signal intensities for eachmiRNAwere
compared across DRGs obtained from tumour‐bearing mice
(n¼ 3) to the sham group of mice (n¼ 3). Although 86 miRNAs
were regulated with 2.0‐fold‐change, we sought to identify the
most prominent changes by focusing on miRNAs which showed
at least 2.5‐fold‐change (up‐ or downregulation) in expression
and with most stringent array and biological replicate standards
(see Materials and Methods Section for detailed description) in
tumour‐bearing mice over sham controls. These were depicted
in form of heat plots (Fig 1C and D). Using these criteria, no
prominent and consistent changes were observed in miRNA
expression between tumour‐bearing mice and sham mice on
PID‐4 (Fig 1C). However, at PID‐8, when strong hypersensitivity
was established, a subset of 57 miRNAs showed striking changes
in expression when compared to sham‐treated mice, which were
consistent over all three biological replicates (Fig 1D); 26
miRNAs were prominently upregulated and 31 miRNAs were
downregulated in tumour‐bearing mice as compared to sham‐
treated mice. Out of these 57 cancer‐pain mediated subset2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1741
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Kiran Kumar Bali et al.of 57 miRNAs, 6 were unannotated and one miRNA namely
mmu‐miR‐197 was withdrawn in subsequent releases of
miRBase (Supporting Information Table S1). Microarray proﬁl-
ing data were conﬁrmed with an independent methodology,
namely quantitative real‐time PCR (qRT‐PCR) at PID‐8. Results
from qRT‐PCR analyses largely matched microarray data
(examples are shown in Fig 1E), although the extent of
regulation tended to be much higher in qRT‐PCR analysis than
from proﬁling analyses.
Manipulating the expression of miRNAs in DRGs in vivo
miRNA inhibitors are single stranded oligos having seed
sequence complimentarity with targetingmiRNA, which inhibits
endogenous miRNA function. miRNA mimics on the other hand
are synthetic double stranded oligos, which mimics endogenous
miRNA expression after entering into the cell. In our hands,
cholesterol‐conjugated antagomirs were not efﬁcacious in
inhibiting expression ofmiRNAs or their target mRNAs following
intrathecal delivery. Therefore, we custom‐designed LNA‐based
miRNA‐inhibitors with shortest possible nucleotide lengths
without considerably enhancing off‐target effects in order to
facilitate cellular permeation (Supporting Information Table S2).
Mis‐match inhibitors were designed as controls in a similar
manner by introducing at least four mismatches into respective
inhibitor sequence, while making sure not to have any sequence
similarity with other mouse miRNA (Supporting Information
Table S1). miRNA inhibitors and mis‐match inhibitors were
delivered intrathecally with an in vivo transfection reagent to
boost tissue uptake, as described recently (Favereaux
et al, 2011). To reverse tumour‐mediated down‐regulation of
candidate miRNAs, we delivered miRNA‐mimics, which were
custom‐designed to carry a 30‐cholesterol conjugation on the
passive, passenger strand (to facilitate in vivo uptake) and a
30‐FITC conjugation on the guide strand (for visualization).
We implanted chronic intrathecal catheters, which permitted
delivery of multiple doses of miRNA inhibitors or mimics,
adapting regimens previously described for delivering small
interfering RNAs to DRGs in rats in vivo (Whitehead et al, 2009;
Wu et al, 2010). Based on previous observations that
intrathecally delivered ﬂuorescence probe‐tagged short‐
oligonucleotides can be detected in the DRGs only up to 24 h
following injection (Layzer et al, 2004; Mook et al, 2010), we
performed multiple administrations of either inhibitor or mimicFigure 1. Up‐ or down‐regulation of microRNAs (miRNAs) in sensory neurons
A. Increase in frequency of paw withdrawal to plantar application of a von Frey fi
bone of the heel in mice as compared to sham surgery.  denotes p¼0.002 o
† denotes p<0.001 on PID-5 and<0.0001 from PID-6 through 15 as compare
measures followed by Bonferroni’s multiple comparisons post hoc test, n¼ a
B. Mechanical response threshold calculated as von Frey filament strength req
through 15 as compared to basal and † denotes p¼0.004 on PID-5, 6 & 13, 0.0
and 0.003 on PID-15 as compared to corresponding data point in the sham gr
comparisons post hoc test, n¼ at least 6 mice per group.
C,D. Heat maps of miRNAs found to be significantly up- or downregulated via micr
or 8 days (D) post implantation as compared to sham surgery. Scale indicat
E. Representation of examples of miRNAs showing up- or down-regulation foll
panel) and the original data frommicroarray analysis. p¼0.001 for miR-544
miR-291b-5p and 0.005 for miR-483-3p as compared to sham-treated grou
EMBO Mol Med (2013) 5, 1740–1758 intrathecally at the lumbar L3‐L4 DRG level in vivo at 24 h
intervals. As shown in the Fig 2, panel B, intrathecally delivered
FAM‐tagged miRNA‐inhibitors (2 nmol/injection in 5ml volume
followed by 5ml saline) could be visualized in whole mount
DRGs at 24 h after a single bolus application; in images at higher
magniﬁcation, ﬂuorescence was detected in the cytoplasm of the
labelled cells throughout the DRG (Fig 2, panel B). Quantitative
analyses are difﬁcult owing to the low level of ﬂuorescence
signals detected from the single FAM molecule tagged per
inhibitor molecule; however, upon confocal analysis of sections
derived from DRGs, 73% of DRG neurons showed an uptake of
FAM‐conjugated inhibitors. In contrast, confocal analysis on
spinal L3/L4 segment sections did not reveal uptake in the spinal
dorsal horn of the same animals (Supporting Information Fig 1).
Moreover, functionality of intrathecally delivered inhibitors or
mimics was validated via qRT‐PCR‐based expression analysis on
lumbar L3, L4 and L5 DRGs 24 h after injection (examples with
knockdown of miR‐1a‐3p and miR‐34c‐3p with their respective
inhibitors in comparison with respective mismatch inhibitors is
shown in Fig 2, panel C; p< 0.05 two tailed t‐test). Along the
same lines, DRGs from mice injected intrathecally with miRNA
mimics showed a strong expression of targeted miRNAs in
comparison to corresponding non‐targeting mimics (examples
with overexpression of miR‐370‐3p and miRNA‐291b‐5p with
their respective mimics in comparison with non‐targeting‐
controls is shown in Fig 2, panel D; p< 0.05 two tailed t‐test).
These approaches for reciprocal modulation of the expression
of deregulated candidate miRNAs in DRG in vivo thus paved the
way for functional experiments in the context of tumour‐pain
model.
Elucidating the functional signiﬁcance of tumour‐associated
upregulation of miRNAs in bone metastatic pain
We then chose a set of six candidate miRNAs for in vivo
functional analysis, which had shown interesting patterns of
expression changes in tumour‐bearing mice. In all of the
behavioural analyses described below,  denotes p 0.05 as
compared to basal values, † denotes p 0.05 relative to
corresponding mismatch inhibitor or mimic for each particular
day of analysis and ‡ denotes p 0.05 relative to vehicle treated
group for particular day of analysis. The statistical analyses were
performed by employing two‐way ANOVA of repeated measures
followed by Bonferroni’s multiple comparisons post hoc test.of the dorsal root ganglia (DRG) in a model of bone metastases pain.
lament force of 0.07 g following induction of tumor growth in the calcaneous
n PID-5, 6, 7 and <0.0001 from PID-8 through 15 as compared to basal and
d to corresponding data point in the sham group, two-way ANOVA of repeated
t least 6 mice per group.
uired to achieve 50% withdrawal frequency.  denotes p<0.001 from PID-4
06 on PID-7, 9 & 11, 0.005 on PID-8, 0.004 on PID-10, 0.0001 on PID-12 & 14,
oup, two-way ANOVA of repeated measures followed by Bonferroni’s multiple
oarray analysis in the ipsilateral lumbar DRG of tumor-bearing mice 4 days (C)
es expression intensities obtained from the microarray experiment.
owing independent verification with quantitative RT-PCR analyses (left hand
-3p, 0.003 for miR-1a-3p, 0.009 for miR-34c-5p, 0.04 for miR-370-3p, 0.03 for
p, ANOVA followed by post hoc Fischer’s test, n¼3 mice per group.
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1743
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Kiran Kumar Bali et al.Because we observed that miR‐1a‐3p is upregulated by >10‐
fold in the DRG at PID‐8 following tumour induction in the
calcaneous bone, we asked whether reversing this pathophysi-
ological induction inﬂuences tumour‐associated hyperalgesia.
Mice were intrathecally injected with either miR‐1a‐3p‐inhibitor
or a mismatch inhibitor (as described above) at a concentration
10 pmol in a total of 10ml volume per injection every 24 h starting
on PID‐4 until PID‐9 (see injection scheme in Fig 2, panel A).
Although both cohorts of mice developed signiﬁcant mechanical
hypersensitivity following tumour induction as compared to
basal behaviour, the magnitude of mechanical hypersensitivity
was signiﬁcantly lesser in mice treated with miR‐1a‐3p‐inhibitor
as compared to mice treated with the corresponding mismatch
inhibitor (Fig 3, panel A). This was also evident by analysing the
50% response threshold (Fig 3, panel B) or the area under the
curve (AUC) of stimulus–response frequency curves for von Frey
forces ranging from 0.02 to 1.0 g (Supporting Information Fig 2,
panel A).
To study miRNA‐34c‐5p, which we found to be upregulated
by sevenfold in the DRGs at PID‐8 following tumour induction,
we designed an inhibitor of 14 nucleotides long to target miR‐
34c‐5p speciﬁcally, i.e. without affecting other miR‐34c family
members, and a corresponding mismatch control inhibitor
(Supporting Information Table S1). Mice treated with the
mismatch inhibitor developed signiﬁcant plantar mechanical
hypersensitivity to von Frey force of 0.07 g (Fig 3, panel C), with
the same time course and amplitude as untreated mice (Fig 1A).
In contrast, mice, which receivedmiR‐34c‐5p inhibitor from PID‐
4 to PID‐9 did not show signiﬁcant tumour‐associated
mechanical hypersensitivity to 0.07 g force on days PID‐7,
PID‐9 and PID‐11 (Fig 3, panel C). When the data were analysed
as response thresholds (Fig 3, panel D) or AUC (Supporting
Information Fig 2, panel B) of stimulus–response frequency
curves for von Frey strength ranging from 0.02 to 1.0 g, treatment
with the miR‐34c‐5p inhibitor was found to impart a signiﬁcant
level of protection against tumour‐associated mechanical
hypersensitivity.
However, not all of the miRNAs which were observed to be
upregulated in DRGs following tumour induction emerged as
functionally relevant in the context of tumour‐associated
mechanical hypersensitivity. For example, inhibiting tumour‐
associated upregulation of miR‐544‐3p, which was a highly
regulated candidate miRNA from the screen, resulted in no
signiﬁcant change in the magnitude of tumour‐associated
mechanical hyperalgesia when compared to corresponding
controls (Fig 3, panels D, E and Supporting Information Fig 2,
panel C; p> 0.05 at all time points tested).Figure 2. Manipulation of miRNA expression in lumbar DRGs in mice in vivo
A. Experimental scheme established in this study which enables effective knockdow
associated behaviours.
B. Microscopic analyses of whole-mount DRGs or cryosections showing uptake o
C. Typical examples of qRT-PCR verification of efficacy of miRNA inhibitors in re
D. Typical examples of qRT-PCR verification of efficacy of miRNA mimics in reversin
miRNAs in ipsilateral DRGs in vivo. In panel (C),  denotes p¼0.02 for miR-1a-3p
panel (D),  denotes p¼0.001 for miR-370-3p and<0.0001 for miR-291b-5p as
n¼3 per group.
EMBO Mol Med (2013) 5, 1740–1758 Elucidating the functional signiﬁcance of tumour‐associated
downregulation of miRNAs in bone metastatic pain
We then proceeded to investigate the functional signiﬁcance of
candidate miRNAs that were downregulated in tumour
conditions by using mimics to counteract tumour‐induced
miRNA downregulation in DRGs. Either a miRNA‐speciﬁc or a
non‐targeting mimic was applied starting the Day 0 of tumour
induction intrathecally until PID‐8 at 2 nmol/injection in 5ml
PBS followed by 5ml saline ﬂush (see injection scheme in Fig 2,
panel A). Interestingly, mice treated with a miR‐370‐3p‐mimic
developed signiﬁcantly more tumour‐induced mechanical
hypersensitivity to a von Frey force of 0.02 g than mice treated
with a non‐targeting control mimic (Fig 4, panel A; p< 0.05).
This was also evident upon comparing response thresholds
(Fig 4, panel B) or AUC (Supporting Information Fig 3, panel A)
of stimulus–response frequency curves over von Frey forces
0.02–1 g. Thus, counteracting tumour‐induced downregulation
of miR‐370‐3p and overexpressing it in DRGs led to exaggerated
tumour‐associated pain, indicating that downregulation of miR‐
370‐3p constitutes an endogenous defense mechanism against
tumour‐pain.
In contrast, a different functional role was observed for miR‐
483‐3p in this model of tumour‐pain. Although mice treated with
a miR‐483‐3p‐mimic developed signiﬁcant mechanical hyper-
sensitivity to 0.07 g of mechanical force following tumour
induction as compared to basal behaviour, the magnitude of
mechanical hypersensitivity observed was signiﬁcantly lesser as
compared to that seen in mice treated with a non‐targeting
control mimic (Fig 4, panel C). Analysis of response thresholds
(Fig 4, panel D) or AUC (Supporting Information Fig 3, panel B)
of stimulus–response frequency curves for von Frey forces
ranging from 0.02–1.0 g revealed similar results. Thus, tumour‐
induced downregulation of miRNA‐483‐3p contributes to
nociceptive hypersensitivity.
Finally, we observed that reversing the down‐regulation of
miRNA‐291b‐5p, another candidate deregulated miRNA from
proﬁling analyses, resulted in no signiﬁcant change in the
magnitude of tumour‐associated mechanical hyperalgesia when
compared to corresponding controls (Fig 4, panels E, F and
Supporting Information Fig 3, panel C, p> 0.05).
Addressing mechanisms underlying miRNA‐mediated
modulation of tumour‐associated hypersensitivity via analysis
of mRNA targets
Having functionally validated several candidate miRNAs, which
emerged from our genome‐wide screen, we then set out to
investigate mechanisms underlying their role in tumour‐via intrathecal application of miRNA mimics and inhibitors.
n/induction of miRNA expression in DRGs in vivo and analysis of tumour pain-
f FAM-conjugated miRNA inhibitors. Scale bar is 50mm in all panels.
versing tumour-induced upregulation of miRNAs in ipsilateral DRGs in vivo.
g tumour-induced downregulation of miRNAs and inducing overexpression of
, 0.04 for miR-34c-3p as compared to correspondingmismatch inhibitor and in
compared to non-targeting mimic, ANOVA followed by post hoc Fischer’s test,
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Kiran Kumar Bali et al.associated mechanical hypersensitivity. Using in silico algo-
rithms for prediction of mRNA targets of miRNAs, we noted that
several important modulators of neuronal excitability and
nociceptive sensitivity are putatively modulated by miRNAs,
which emerged from our screen. Due to very large volume of
these in silico data sets, we focus here on one particular
deregulated miRNA to present a comprehensive overview in the
context of tumour pain, starting from in silico prediction of
mRNA targets, qRT‐PCR validation of predictions, promoter
analysis of one speciﬁc key mRNA to verify mRNA–miRNA
pairing, analysis of it’s modulation in vivo and ﬁnally, in vivo
functional analysis of the mRNA target in tumour‐associated
pain. For this purpose, we chose miRNA‐1a‐3p as our prototypic
miRNA for detailed mechanistic analysis for various reasons (see
Discussion Section). As the ﬁrst step, we followed an unbiased
and comprehensive approach to predict the mRNAs targets for
miRNA‐1a‐3p by adapting 14 different state‐of‐art algorithms
(Supporting Information Table S3), which utilize different
parameters, such as seed region complementarily and thermody-
namic stability to predict the targets of a given miRNA. Reasoning
that a transcript predicted as a target by several algorithms is likely
to be a bona‐ﬁde, biologically signiﬁcant target in terms of
miRNA–mRNA pairing, we derived a condensed list of 53
candidate mRNA targets for the miRNA‐1a‐3p.
To comprehensively exclude false positives or targets that
may be regulated only modestly, we directly analysed the impact
of miRNA‐1a‐3p inhibition on the expression of all 53 targetFigure 3. Functional validation of miRNAs upregulated in DRGs in tumour be
A. Change in frequency of paw withdrawal to plantar application of a von Frey fil
bone of the heel in mice receiving intrathecally delivered miR-1a-3p inhibito
vehicle (grey symbols).  denotes p<0.0001 on PID-5 through 15 in the vehic
† denotes p¼0.007 on PID-10 and <0.0001 on PID-12 & 14 as compared to co
on PID-10, 12 & 14 as compared to corresponding data point in the vehicle g
B. Mechanical response thresholds calculated as von Frey filament strength requir
in the calcaneous bone of the heel in mice receiving intrathecally delivered m
(green bars) or vehicle (grey bars).  denotes p<0.0001 from PID-5 through 14 i
1a-3p-inhibitor groupas compared to basal; † denotes p¼0.004 on PID-5, 0.00
data point in the mismatch inhibitor group; ‡ denotes p<0.0001 on PID-5, 0
corresponding data point in the vehicle group.
C. Change in frequency of paw withdrawal to plantar application of a von Frey fil
bone of the heel in mice receiving intrathecally delivered miR-34c-5p inhibito
vehicle (grey symbols).  denotes p<0.0001 on PID-5 through 14 in the vehicl
miR-34c-5p- inhibitor group as compared to basal; † denotes p<0.0001 on PID
group; ‡ denotes p<0.0001 on PID-7, 9 & 11 as compared to corresponding
D. Mechanical response thresholds calculated as von Frey filament strength requir
in the calcaneous bone of the heel in mice receiving intrathecally delivered miR
bars) or vehicle (grey bars).  denotes p¼0.0003 on PID-7 & 9,<0.0001 on PID
PID-14 in the miR-34c-5p-inhibitor group and 0.0001 on PID-5 through 15 in
PID-11 as compared to corresponding data point in the mismatch inhibitor gro
corresponding data point in the vehicle group.
E. Change in frequency of paw withdrawal to plantar application of a von Frey fil
bone of the heel in mice receiving intrathecally delivered miR-544-3p inhibito
vehicle (grey symbols).  denotes p<0.0001 from PID-3 through PID-14 in ve
F. Mechanical response thresholds calculated as von Frey filament strength requir
in the calcaneous bone of the heel in mice receiving intrathecally delivered miR
bars) or vehicle (grey bars).  denotes p<0.0001 from PID-3 through PID-14
In all panels statistical significance was tested by two-way ANOVA of repeated mea
6 mice per group. The experimental scheme employed is the same as described
mismatch-inhibitor or vehicle application.
EMBO Mol Med (2013) 5, 1740–1758 mRNAs in the DRG in vivo. Using a nanostring device, which
digitally quantiﬁes a wide set of mRNA transcripts starting from
a very low quantity of tissue, we analysed RNA samples obtained
from DRGs of mice which received intrathecal injections of
10 pmol of miRNA‐1a‐3p inhibitor or mismatch inhibitor in vivo
every 24 h with in vivo transfection reagent from PID‐4 to PID‐9.
Following qRT‐PCR‐based conﬁrmation of the inhibition of
miRNA‐1a‐3p by it’s speciﬁc inhibitor, we then analysed the
expression of 53 predicted targets in relation to that of
ﬁve housekeeping genes, namely clathrin, heavy polypeptide
(Cltc), glyceraldehyde‐3‐phosphate dehydrogenase (Gapdh),
glucuronidase beta (Gusb), hypoxanthine guanine phosphor-
ibosyl transferase (Hprt) and tubulin, beta 5 class I (Tubb5).
Amongst these, the expression of 3 targets, namely insulin‐like
growth factor 1 (Igf1), heart and neural crest derivatives
expressed transcript 2 (Hand2) and Chloride channel 3
(Clcn3) (Fig 5, panel A), was strongly enhanced upon
suppression of miRNA‐1a‐3p expression, suggesting miRNA–
mRNA pairing.
Dysregulation of Clcn3 expression in the DRG in bone
metastatic pain and it’s relation to miR‐1a‐3p
Owing to the potential impact of chloride channels on neuronal
excitability, we were particularly interested in characterizing
Clcn3 as a new target of miR‐1a‐3p. Based upon the
above results, we were intrigued by the question whether
modulation of Clcn3 expression directly contributes to thearing mice with respect to tumour‐induced mechanical hypersensitivity.
ament force of 0.07 g following induction of tumor growth in the calcaneous
r (red symbols) or the corresponding mismatch inhibitors (green symbols) or
le, mismatch inhibitor and miR-1a-3p inhibitor groups as compared to basal;
rresponding data point in the mismatch inhibitor group; ‡ denotes p<0.0001
roup.
ed to achieve 50% withdrawal frequency following induction of tumor growth
iR-1a-3p inhibitor (red bars) or the corresponding mismatch inhibitors
n the vehicle and mismatch inhibitor groups and on PID-10, 12, 14 in the miR-
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ament force of 0.07 g following induction of tumor growth in the calcaneous
r (red symbols) or the corresponding mismatch inhibitor (green symbols) or
e and mismatch inhibitor groups, 0.006 on PID-5 and<0.0001 on PID-14 for
-7, 9 & 11 as compared to corresponding data point in the mismatch inhibitor
data point in the vehicle group.
ed to achieve 50% withdrawal frequency following induction of tumor growth
-34c-5p inhibitor (red bars) or the corresponding mismatch inhibitors (green
-11 & 14 in the mismatch-inhibitor group; 0.0018 on PID-5 and<0.0001 on
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sures followed by Bonferroni’s multiple comparisons post hoc test, n¼ at least
in Fig. 2A. The square box represents the time-course of miRNA-inhibitor or
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1747
0 
20 
40 
60 
80 
100 
Vehicle non-targeting  mimic 
miR-370-3p  
mimic 
Days after tumor implantation 
* 
Fr
eq
ue
nc
y 
 o
f  
w
ith
dr
aw
al
  (
%
) 
*, †,  ‡ 
*, †,  ‡ 
*, †,  ‡ 
*, †,  ‡ 
PID 0-7 
Fr
eq
ue
nc
y 
 o
f  
w
ith
dr
aw
al
  (
%
) 
Vehicle non-targeting  mimic 
miR-291b-5p  
mimic 
Days after tumor implantation 
0 
20 
40 
60 
80 
100 
* 
* 
* * 
* 
* 
* * 
* 
* * 
* 
PID 0-7 
Vehicle Non-targeting mimic 
miR-483-3p  
mimic 
Days after tumor implantation 
M
ec
ha
ni
ca
l r
es
po
ns
e 
th
re
sh
ol
d 
(g
)  
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
* 
* * * * * * 
* * 
* 
* 
* 
* 
* * 
0 
20 
40 
60 
80 
100 
Vehicle non-targeting  mimic 
miR-483-3p  
mimic 
Days after tumor implantation 
Fr
eq
ue
nc
y 
 o
f  
w
ith
dr
aw
al
  (
%
) 
* * 
* 
* * 
* * * 
* 
*, † *, †,  ‡ 
* 
* 
* 
PID 0-7 
* 
A  B  
C  D  
E  F  
Vehicle Non-targeting mimic 
miR-370-3p  
mimic 
Days after tumor implantation 
M
ec
ha
ni
ca
l r
es
po
ns
e 
th
re
sh
ol
d 
(g
) 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
* * * 
* 
* * 
* * * * 
* * 
*
† * 
† 
‡ 
* 
† 
‡ 
* 
† 
‡ 
Vehicle Non-targeting mimic 
miR-483-3p  
mimic 
Days after tumor implantation 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
M
ec
ha
ni
ca
l r
es
po
ns
e 
th
re
sh
ol
d 
(g
) 
* 
* 
* * * 
* 
* * * * * * 
* 
* 
* 
† 
‡ 
* 
† 
‡ 
Figure 4.
Research Article www.embomolmed.org
Sensory miRNAs in cancer pain
1748  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1740–1758
3Research Articlewww.embomolmed.org
Kiran Kumar Bali et al.functional role, which we observed for miRNA‐1a‐3p in the bone
metastatic model (above). Interestingly, qRT‐PCR analysis on
DRGs from tumour‐bearing mice revealed that at PID‐8, a time
point at which we had initially observed that miRNA‐1a‐3p is
upregulated (Fig 1, panel E), the expression levels of Clcn3
mRNA are signiﬁcantly lower than levels in basal state or sham
controls (Fig 5, panels B and C; two‐tailed t‐test assuming equal
variances). In contrast, expression of Igf1 and Hand2 was not
signiﬁcantly altered at PID‐8 (Fig 5, panel B). To conﬁrm the
change in Clcn3 mRNA expression in the DRGs of tumour‐
bearing mice, we performed a qRT‐PCR‐based analysis of the
time‐course of regulation at different time points after tumour
cell implantation as compared with sham controls at each time
point. We observed that Clcn3 is signiﬁcantly and consistently
downregulated starting from PID‐4 until PID‐15 (Fig 5, panel C),
which is in complete agreement with the time‐course of
development of tumour‐induced mechanical hyperalgesia
(Fig 1A). Moreover, this ﬁts to the time‐course of miR‐1a‐3p
upregulation in ipsilateral DRGs following tumour induction
(Fig 5, panel D, two‐tailed t‐test assuming equal variances).
Taken together with the ex vivo analyses, these experiments
underscore the tight reciprocal association between the expres-
sion of miRNA‐1a‐3p and Clcn3 and established their in vivo
validity as a miRNA–mRNA modulatory pair in DRGs of tumour‐
bearing mice.
Using a previously characterized antibody directed against
mouse Clcn3 protein (Matsuda et al, 2008), we detected
Clcn3 immunoreactivity in a majority of DRG neurons (Fig 5,Figure 4. Functional validation of miRNAs downregulated in DRGs in tumor b
A. Change in frequency of paw withdrawal to plantar application of a von Frey fil
bone of the heel in mice receiving intrathecally delivered miR-370-3p mimic (re
p¼0.0192 on PID-13 in the vehicle group and <0.0001 on PID-8 through 15 in
PID-8 and<0.001 on PID-10, 13 & 15 as compared to corresponding data point
PID-10 & 15 and 0.0044 on PID-13 as compared to corresponding data point
B. Mechanical response thresholds calculated as von Frey filament strength requir
in the calcaneous bone of the heel in mice receiving intrathecally deliveredm
(grey bars).  denotes p¼0.0291 on PID-8, 0.05 on PID-10, 0.0192 on PID-13 a
on PID-13 & 15 in the non-targeting mimic group; † denotes p¼0.0013 on P
in the non-targeting mimic group; ‡ denotes p¼0.0013 on PID-6 and <0.000
group.
C. Change in frequency of paw withdrawal to plantar application of a von Frey fil
bone of the heel in mice receiving intrathecally delivered miR-483-3p mimic (re
p¼0.0008 on PID-6, 0.0002 on PID-8 & <0.0001 on PID-10, 13, 15 in vehicle
† denotes p¼0.0206 on PID-10 & 0.0074 on PID-13 as compared to correspond
PID-13 as compared to corresponding data point in the vehicle group.
D. Mechanical response thresholds calculated as von Frey filament strength requir
in the calcaneous bone of the heel in mice receiving intrathecally deliveredm
(grey bars).  denotes p<0.0001 from PID-3 through 15 in vehicle, non-targe
† denotes p¼0.005 on PID-10 & 0.05 on PID-13 as compared to correspondin
PID-10, 0.022 on PID-13 as compared to corresponding data point in the veh
E. Change in frequency of paw withdrawal to plantar application of a von Frey fil
bone of the heel inmice receiving intrathecally deliveredmiR-291b-5pmimic (re
p<0.0001 from PID-3 through PID-14 in vehicle, non-targeting-mimic and m
F. Mechanical response thresholds calculated as von Frey filament strength requir
in the calcaneous bone of the heel in mice receiving intrathecally deliveredmiR-
bars).  denotes p<0.0001 from PID-3 through PID-14 in vehicle, non-target
In all panels, statistical significance was tested by two-way ANOVA of repeatedmea
6 mice per group. The experimental scheme employed is the same as described
non-targeting-mimic or vehicle application.
EMBO Mol Med (2013) 5, 1740–1758 panel E). Control sections stained with secondary antibodies
alone did not reveal auto ﬂuorescence (Supporting
Information Fig 4). Co‐labelling experiments indicated anti‐
Clcn3 immunoreactivity overlapped with CGRP expression and
isolectin‐B4‐binding, which constitute markers of peptidergic
and non‐peptidergic nociceptive neurons, respectively (Fig 5,
panel E).
Validation of Clcn3 as a target for miR‐1a‐3p
In silico analysis indicated that miR‐1a‐3p can bind to the 3 prime
untranslated region (30UTR) of the mouse Clcn3 gene (Fig 6,
panel A). To conﬁrm that miRNA‐1 is able to functionally bind to
30 UTR of Clcn3 and modulate it’s expression, we constructed a
luciferase reporter vector in which the 30UTR of Clcn3 mRNA
was fused to the luciferase coding sequence under pGK promoter
in dual luciferase vector (pmiRGLO vector). In a HEK293 cell‐
based heterologous expression system, either miR‐1a‐3p or
mismatch inhibitors were co‐transfected with the Clcn3 reporter
vector. In a parallel experiment, either miR‐1a‐3p mimic or non‐
targeting mimic were co‐transfected with the Clcn3 reporter
vector and luciferase expression was measured 48 h thereafter.
Expression of miR‐1a‐3p inhibitor dose‐dependently increased
the translation of luciferase protein from the Clcn3 reporter
construct, whereas expression of the miR‐1a‐3p mimic exerted
the opposite effect (Fig 6, panels B and C, p< 0.05, as compared
to control samples, two tailed t‐test). These results demonstrate
that miR‐1a‐3p directly targets the Clcn3 30UTR region to
modulate its expression.earing mice with respect to tumor‐induced mechanical hypersensitivity.
ament force of 0.02 g following induction of tumor growth in the calcaneous
d symbols) or non-targeting mimic (green) or vehicle (grey symbols).  denotes
the miR-370-3p-mimic group as compared to basal; † denotes p¼0.0013 on
in the non-targeting mimic group; ‡ denotes p¼0.0003 on PID-8,<0.0001 on
in the vehicle group.
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sures followed by Bonferroni’s multiple comparisons post hoc test, n¼ at least
in Fig. 2A. The square box represents the time-course of miRNA-mimic or
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Kiran Kumar Bali et al.Knock‐down of Clcn3 leads to enhanced tumour‐induced
mechanical hypersensitivity
Finally, we tested the functional signiﬁcance of knocking down
Clcn3 expression in DRG in the context of tumour‐induced
hypersensitivity. A pool of siRNAs designed against Clcn3mRNA
(Clcn3‐siRNA) or non‐targeting siRNA (control‐siRNA) were
applied intrathecally (5ml at 1.2mg/ml siRNA with in vivo
transfection reagent), which led to a signiﬁcant knock‐down of
Clcn3 expression within 48 h of a single dose of Clcn3‐siRNA as
compared to control‐siRNA (Fig 6, panel D, p< 0.05, as
compared to control samples, two tailed t‐test). For behavioural
analysis in the tumour pain model, siRNAs were injected from
PID‐0 until PID‐8 every 24 h and the development of tumour‐
mediated mechanical hypersensitivity was monitored using
calibrated von Frey ﬁlaments from PID‐3 until PID‐15 on
every alternate day. Interestingly, a knockdown of Clcn3
expression in DRG was associated with exaggerated mechanical
hypersensitivity to plantar application of von Frey stimuli in
tumour‐bearing mice. Whereas control siRNA‐treated mice
did not develop any hypersensitivity to extremely low
magnitude of mechanical force, such as in response to the
von Frey ﬁlament exerting 0.02 g force until 11 days after
tumour‐induction, Clcn3‐siRNA‐treated mice showed signiﬁcant
hypersensitivity to 0.02 g from PID‐5 onwards (Fig 6, panel E).
Moreover, starting from PID‐5, mice treated with Clcn3‐siRNA
demonstrated signiﬁcantly stronger decrease in the mechanical
threshold than control‐siRNA‐treated mice (Fig 6, panel F). Thus
downregulating expression of Clcn3 in the DRG exerted
the same functional effect on tumour‐associated mechanical
hypersensitivity as inhibition of miR‐1a‐3p, again emphasizing
the in vivo signiﬁcance of miR‐1a‐3p‐Clnc3 as a miRNA–mRNA
regulatory pair.
To investigate whether Clcn3 is also involved in the
modulation of basal mechanical sensitivity, we performed Clcn3
knockdown in L3‐L4 DRGs of wild‐type mice in the absence of
tumour induction. While mice receiving control‐siRNA showed
no signiﬁcant alterations in responses to von Frey stimuli, mice
treated with the Clcn3‐siRNA developed signiﬁcant mechanical
hypersensitivity (responses to 0.02 g stimulation are shown in
Supporting Information Fig 5, panel A). Analysis of mechanical
response thresholds revealed similar results (Supporting Infor-
mation Fig 5 panel B). However, the magnitude of increase in the
mechanical sensitivity upon Clcn3 knock‐down in naïve mice
was lesser in magnitude than when compared to magnitude ofFigure 5. Analysis of miR‐1a‐3p target genes in the context of tumor‐induce
A. QRT-PCR analysis demonstrating induction of predicted miR-1a-3p target gen
inhibitor delivery intrathecally in vivo.  denotes p<:0.0001 as compared to
B. QRT-PCR analysis representing changes in expression of miR-1a-3p target gen
 denotes p¼0.041 as compared to sham group.
C. Time course of tumor-induced downregulation of Clcn3 expression in ipsilatera
PID-8, 0.05 on PID-10 and 0.04 on PID-15 as compared to sham group.
D. Time course of tumor-induced changes in miR-1a-3p expression in ipsilateral lu
and 0.04 on PID-10 as compared to sham group.
In panels A, B, C &D statistical P value was calculated by ANOVA followed by
E. Immunohistochemical analysis of expression of Clcn3 protein in mouse DRG an
peptidergic (CGRP-positive) nociceptors. Scale bars represent 50mm.
EMBO Mol Med (2013) 5, 1740–1758 the effect of Clcn3‐siRNA on tumour‐mediated hyperalgesia,
consistent with a regulation of Clcn3 expression in tumour states.DISCUSSION
Despite recent advances, cancer pain remains a major challenge
for clinicians and basic scientists and there is an urgent demand
for the development of speciﬁc mechanism‐based therapies.
Using a comprehensive approach combining genome‐wide
miRNA screening, molecular and in silico analyses with
behavioural approaches in a clinically relevant model of
metastatic bone‐cancer pain, we now show that tumour‐induced
hypersensitivity is associated with a dysregulation of miRNA
expression in sensory neurons corresponding to tumour‐affected
areas. This is the ﬁrst study proﬁling genome‐wide miRNA
expression and their functional importance in the development
and maintenance of tumour‐mediated chronic pain. Further-
more, whereas previous studies on the involvement of miRNAs
in other forms of pain disorders, e.g. neuropathic pain, have
either addressed miRNA proﬁling without functional analysis or
have focussed on a single target gene modulated by a miRNA
(Aldrich et al, 2009; Bai et al, 2007; Favereaux et al, 2011), the
present study spans multiple levels of analysis starting with a
genome‐wide identiﬁcation of the miRNA regulatory network of
cancer pain‐associated miRNAs in sensory neurons, their
functional validation in vivo all the way to the identiﬁcation,
molecular characterization and functional validation of a novel
target gene.
Our in vivo analyses revealed that the expression of 57
miRNAs amongst the 615 tested mouse miRNAs is dysregulated
in sensory neurons of the DRG directly under the inﬂuence of
tumour growth in their innervation territory, representing a
novel and intriguing aspect of tumour–nerve interactions.
Interestingly, miRNA dysregulation only became evident when
pronounced tumour‐induced hypersensitivity was established,
but did not manifest at the beginning stages (e.g. 4 days post‐
implantation). This suggests that early periods of tumour pain
likely result from local interactions between tumour cells and
nerves, which lead to sensitization of nerve afferents, and that
miRNA dysregulation and the resulting changes in the
expression of a multitude of genes in sensory neurons
rather contribute to the maintenance and long‐term nature of
tumour pain. This study was based upon a model involvingd hypersensitivity in the bone metastatic pain model.
es in lumbar DRGs in vivo following suppression of miR-1a-3p expression via
mismatch-inhibitor group.
es in ipsilateral lumbar DRGs in vivo at day 8 in the bone metastases model.
l lumbar DRGs via QRT-PCR analysis.  denotes p¼0.002 on PID-4, 0.003 on
mbar DRGs via QRT-PCR analysis.  denotes p¼0.04 on PID-4, 0.002 on PID-8,
post hoc Fischer’s test, n¼3 mice per group.
d colabeling with isolectin-B4-binding (IB4) non-peptidergic nociceptors and
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1751
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1752tumour‐induced remodelling of bone and ensuing mechanical
hypersensitivity in the adjacent skin. It will be interesting in
future studies to compare miRNA expression proﬁles with
models based upon direct injection of tumour cells in the skin to
work out the component of bone pain.
In contrast to tissues such as liver, heart, blood vessel and the
lymphatic system, amongst others, which are amenable to
modulation via exogenously delivered miRNA modulators
(Bernardo et al, 2012; Krutzfeldt et al, 2005, 2007; MuramatsuA
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system is notoriously difﬁcult to target (Long & Lahiri, 2012). To
disrupt the pathophysiological induction or downregulation of
miRNA in DRGs in vivo, we established effective protocols for
intrathecal delivery of miRNA inhibitors or mimics and
demonstrated the efﬁcacy of selective manipulations in miRNA
expression in vivo. Our behavioural analysis in the bone‐
metastases model indicated that inhibiting the tumour‐induced
upregulation of miR‐1a‐3p ormiR‐34c‐5p, but not ofmiRNA‐544‐4 2 
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Kiran Kumar Bali et al.3p, in sensory neurons markedly attenuated tumour‐mediated
hyperalgesia. Furthermore, reversing pathophysiological de-
crease of miR‐483‐3p, but not of miR‐291b‐5p, attenuated
tumour‐mediated hyperalgesia. In contrast, augmenting the
expression of miR‐370‐3p in DRGs led to exaggerated tumour‐
mediated hyperalgesia. Thus, the approach established and
described in this study provides proof‐of‐principal that it is
effective and valuable in elucidating the functional contributions
of miRNAs. An intriguing observation is that even though
injection of miRNA modulators was stopped at PID‐9, the effect
persisted until PID‐15. As it has been shown that short‐
oligonucleotides can be detected in the DRGs up to 24 h
following injection (Layzer et al, 2004; Mook et al, 2010), the
change in miRNA expression will persist until at least 24 h
thereafter, i.e. PID‐10. Since there is a time lag between miRNA
action and a change in the expression of the protein product of
the ﬁnal target gene(s), the physiological effect resulting from
altered protein function could come about over several days
thereafter. Another interesting ﬁnding from our proﬁling
analyses is, among 43 potentially novel, unannotated miRNAs
(classiﬁed as solexa sequences) several were observed to be
strongly expressed in DRG and 10 showed signiﬁcant dysregu-
lation in expression in tumour‐bearing as compared to sham‐
treated mice. It will be interesting in future studies to
systematically elucidate the contributions of all annotated as
well as novel miRNAs which were found to be dysregulated in
conditions of bone metastatic pain.
Here, we chose miRNA‐1a‐3p as our prototypic miRNA for
detailed mechanistic analyses owing to several reasons. One,
although miR‐1a‐3p was characterized to be a non‐neuronal
miRNAwith expression levels in the central nervous system 100‐
to 1000‐fold lesser when compared to cardiac tissue (Mishima
et al, 2007), later studies showed that miR‐1a‐3p is expressed
in sensory neurons of the DRG in mice as well as humansFigure 6. In vitro and in vivo validation of Clcn3 as a miR‐1a‐3p target gene and
in the bone metastatic pain model employed.
A. Binding sites for miR-1a-3p (mmu-miR-1) on the 3’ untranslated region (UTR
B. Luciferase-reporter based assay in HEK293 cells demonstrating changes in tra
graded delivery of the specific inhibitor. p¼0.04, 0.02 and 0.05 for 6, 4 & 2mg
t-test, n¼3 independent experiments.
C. Luciferase-reporter based assay in HEK293 cells demonstrating changes in tra
expression via graded delivery of the specific mimic. p¼0.03, & 0.02 for 4 & 2m
t-test, n¼3 independent experiments.
D. QRT-PCR analysis demonstrating significant knockdown of Clcn3 expression in l
the corresponding control non-targeting siRNA, p¼0.001 as compared to na
E. Change in frequency of pawwithdrawal to plantar application of von Frey filame
of the heel in mice receiving intrathecally delivered siRNA directed against Clcn
vehicle (grey symbols).  denotes p¼0.0006 on PID-11, and <0.0001 on PID-1
group, 0.0037 on PID-5, and <0.0001 on PID-7 through 15 for the Clcn3-siRNA
PID-7 and<0.0001 on PID-9, 11, 13 & 15 as compared to corresponding data p
represents the time-course of Clcn3-siRNA or non-targeting-siRNA or vehicle
F. Mechanical response thresholds calculated as von Frey filament strength requir
in the calcaneous bone of the heel in mice receiving intrathecally deliveredsiRN
(green bars) or vehicle (grey bars).  denotes p¼0.0003 on PID-5 & 9, 0.0233 on
0.002 on PID-7 and <0.0001 on PID-9, 11, 13 & 15 for the non-targeting-siRNA
compared to basal; † denotes p¼0.0122 on PID-5, 0.0024 on PID-7, 0.0127
non-targeting-siRNA group and ‡ denotes p¼0.0122 on PID-5, 0.0002 on PID-
point in the vehicle group.
EMBO Mol Med (2013) 5, 1740–1758 (Bastian et al, 2011), which imparts it a particular translational
signiﬁcance; moreover, it has been well‐characterized via
in situ hybridization analysis to be localized to peptidergic
nociceptors (Bastian et al, 2011). Secondly, mimicking miR‐1a‐
3p in neuronal cultures attenuates neurite outgrowth (Bastian
et al, 2011). Third, our results on regulation of miR‐1a‐3p
expression in bone metastatic pain emerged to be intriguingly
different to known ﬁndings in the context of neuropathic and
inﬂammatory pain; whereas inﬂammatory pain as well as partial
sciatic ligation are associated with a decrease in miR‐1a‐3p
expression in the DRG and spinal cord, sciatic nerve axotomy
induces a robust increase in miR‐1a‐3p expression in the DRG
and a corresponding decrease in the spinal cord (Kusuda
et al, 2011). Here, we observed that miRNA‐1a‐3p was highly
upregulated in the DRG in bone metastatic pain. Despite
insights into it’s dysregulation in inﬂammatory and neuropathic
states, the functions of miR‐1a‐3p in pain modulation had not
been analysed so far. Our in vivo analyses revealed as miR‐1a‐3p
in the DRG to be a functionally important positive modulator of
bone metastatic pain, indicating a pronociceptive function for
miR‐1a‐3p.
Based on these intriguing ﬁndings, we sought to identify
genes regulated by miR‐1a‐3p in DRG neurons in an effort to
work out mechanistic details. In doing so, we established and
validated an approach to narrow down and select relevant genes
from the very long lists of target genes, which typically emerge
from in silico analyses. Thus, out of 62 mRNAs putative targets
formiR‐1a‐3p predicted by at least 2 out of 14 algorithms applied,
only 25 showed at least 50% up‐regulation following miR‐1a‐3p
inhibition in sensory neurons in vivo, thereby cautioning about
the strength of interpretations that can be made from in silico
analyses alone. Interestingly, except for Hand2 and Igf1, almost
all of genes that were functionally validated as miR‐1a‐3p targets
in other systems were not found to be regulated by miR‐1a‐3pits functional contribution to tumor‐inducedmechanical hypersensitivity
) of the mouse Clcn3 gene.
nslation of the Clcn3 gene following suppression of miR-1a-3p expression via
/L miR-1a-3p inhibitor groups respectively as compared to control, Student’s
nslation of the Clcn3 gene following suppression or induction of miR-1a-3p
g/L miR-1a-3p inhibitor groups respectively as compared to control, Student’s
umbar DRG following intrathecal delivery of a siRNA directed against Clcn3 or
ive group, ANOVA followed by post hoc Fischer’s test, n¼3 mice per group.
nt forces of 0.02 g following induction of tumor growth in the calcaneous bone
3 (red symbols) or the corresponding non-targeting siRNA (green symbols) or
3 & 15 in the vehicle group, <0.0001 on PID-15 in the non-targeting siRNA
group as compared to basal, † and ‡ denotes p¼0.0202 on PID-5, 0.0011 on
oint in the non-targeting siRNA or vehicle groups respectively. The square box
application.
ed to achieve 80% withdrawal frequency following induction of tumor growth
A directed against Clcn3 (red bars) or the corresponding non-targeting siRNA
PID-7, and<0.0001 on PID-11, 13 & 15 in the vehicle group, 0.0003 on PID-5,
group and <0.0001 from PID-5 through PID-15 for the Clcn3-siRNA group as
on PID-9, 0.05 on PID-11 as compared to corresponding data point in the
7, 0.0029 on PID-9, and 0.0401 on PID-11 as compared to corresponding data
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1753
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1754inhibition in sensory neurons, thereby highlighting the context‐
dependence of functionality of miRNA function and gene
regulation. One of the most interesting aspects of this study was
the identiﬁcation of Clcn3, a chloride channel, as a functionally
important gene target of miR‐1a‐3p in sensory neurons of the
DRG. Apart from evidence for miRNA‐1a‐3p binding to the
30UTR of Clcn3 and regulation of it’s translation, the ﬁnding that
the expression of Clcn3 expression is reciprocally regulated with
respect to miR‐1a‐3p expression in the DRG following peripheral
tumour induction established Clcn3 as a miR‐1a‐3p target in
sensory neurons. Furthermore, the phenotype of exaggerated
tumour‐mediated hyperalgesia evoked by speciﬁcally knocking
Clcn3 expression down in sensory neurons in vivo matched
perfectly with attenuation of tumour‐mediated hyperalgesia
evoked by miR‐1a‐3p knockdown in the DRG. There are several
ways via which Clcn3‐mediated Cl ﬂux could affect sensory
neuron function. For example, it has been shown to be required
for lysophosphatidic acid (LPA)‐activated Cl current activity in
myoﬁbroblast differentiation (Yin et al, 2008), a molecular
pathway which may be relevant to sensory neurons given that
LPA is a highly potent and important modulator of sensory
neuron function in pain disorders (Inoue et al, 2004;
Ueda, 2008). Importantly, Clcn3 plays a role in both acidiﬁcation
and transmitter loading of GABAergic synaptic vesicles, which is
very interesting in the light of the important role for GABAergic
function in sensory terminals of nociceptors (Witschi
et al, 2011). Moreover, in brain tissue, functional interactions
between Clcn3 and Ca2þ/calmodulin‐dependent protein kinase
II have been reported (CamKII) (Cuddapah & Sontheimer, 2010;
Huang et al, 2001), which could be relevant to the pain
modulatory role of CamKII (Crown et al, 2012). Thus, the miR‐
1a‐3p‐Clcn3 miRNA–mRNA regulation pair holds tremendous
potential for modulating pain over multiple ways. A more
detailed analysis of Clcn3 expression and sub‐cellular distribu-
tion in the future could be very insightful; similarly, it will be
interesting to study whether the role of Clcn3 observed here in
the context of cancer pain also extends to the modulation of
inﬂammatory or neuropathic pain states, given especially our
observation that knocking down the basal expression of Clcn3
by itself signiﬁcantly impacted on mechanical sensitivity in the
absence of tumour growth.
Here, miR‐34c‐5p emerged as another key pronociceptive
miRNA, which is induced in sensory neurons of the DRG in bone
metastatic pain. Induction of this miRNA has been previously
implicated in the hippocampus in the context of memory
impairment and in the amygdala in the context of stress
(Haramati et al, 2011; Zovoilis et al, 2011). Several notable
pain modulatory genes are to be found amongst the in silico
prediction list of miR‐34c‐5p target genes, including Cacnb3 (the
gene encoding calcium channel, voltage‐dependent, beta 3
subunit), Gabra3 and Gabra1 (encoding GABA‐A receptor,
subunits alpha 3 and 1, respectively), Scn2b (sodium channel,
voltage‐gated, type II, beta), Bdnf (encoding brain derived
neurotrophic factor), Calca (encoding calcitonin/calcitonin‐
related polypeptide, alpha), Il6st (encoding interleukin 6 signal
transducer), Ednrb (endothelin receptor type B), amongst many
others, which are known to signiﬁcantly impact on pain (De 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Jongh et al, 2003; Enna & McCarson, 2006; Griswold et al, 1999;
Knabl et al, 2008; Li et al, 2012; Murakami et al, 2007; Obata &
Noguchi, 2006; Pedersen et al, 2007; Quarta et al, 2011;
Waxman, 2010). Similarly, miR‐370‐3p, which was known in the
context of angina pectoris and tumour suppression so far
(Hoekstra et al, 2010; Zhang et al, 2012), emerged as a pro‐
nociceptive miRNA. Our in silico analyses revealed many
interesting nociception related genes have binding sites for
miR‐370‐3p, including gene encoding the purinergic receptor
P2X, ligand‐gated ion channel, 3 (P2rx3), opioid receptor, delta 1
(Oprd1), runt related transcription factor 1 (runx1), calcium
channel, voltage‐dependent, alpha 2/delta subunit 2 (Cacna2d2)
among others, which have been characterized functionally in
previous studies (Abrahamsen et al, 2008; Boroujerdi et al, 2011;
Chen et al, 2006; Scherrer et al, 2010; Taylor & Garrido, 2008).
Further detailed analyses will reveal which of these putative
targets mediate the pronociceptive functions of miR‐34c‐5p and
miR‐370‐3p in the context of cancer pain. Finally, two of the six
dysregulated miRNAs analysed did not reveal a functional
impact on tumour hypersensitivity. This is, however, not
surprising since tumour–nerve interactions can encompass
many other functional changes, e.g. cell death in the DRG,
neuropathy, immune inﬁltration, etc., which were not studied
here as readouts and represent interesting options for further
detailed analyses.
Thus, the results of this study deliver valuable new insights
intomechanisms of cancer pain. Furthermore, they open up very
attractive therapeutic options since potential caveats associated
withmiRNAs andmiRNA derivatives, e.g. ‘off‐target’ effects, can
be overwhelmed in this fast‐developing ﬁeld on the way towards
the therapeutic development. Importantly, ncRNA‐based diag-
nostics and therapeutics may have superior advantages by
targeting multiple pain‐associated genes simultaneously, and
this study provides a preclinical basis in the context of cancer‐
associated pain.MATERIALS AND METHODS
Animal model of tumour‐evoked pain
All animal usage procedures were in accordance with ethical guidelines
laid down by the local governing body (Regierungspräsidium
Karlsruhe). All behavioural measurements were done in awake,
unrestrained, age‐matched adult (more than 2 months old) C3H/
HeNCrl mice. The model of bone metastases‐associated pain was
implemented as described previously (Cain et al, 2001; Schweizerhof
et al, 2009). Brieﬂy, National Collection of Type Cultures (NCTC) clone
2472 ﬁbrosarcoma cells (ATCC, Manassas, VA, USA) were cultured and
injected into and around the calcaneus bone of wild type C3H/HeNCrl
mice as described previously (Cain et al, 2001; Schweizerhof
et al, 2009). An equal of saline was injected in the calcaneous bone
in sham‐treated mice.
Measurement of mechanical sensitivity
Micewith tumour implantation or sham treatment were tested for paw
withdrawal behaviour towards graded von Frey ﬁlaments (0.02, 0.07,
0.16, 0.4 and 1.0 g) applied to the plantar surface of the ipsilateral hindEMBO Mol Med (2013) 5, 1740–1758
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Kiran Kumar Bali et al.paw, as we have described in details previously (Schweizerhof
et al, 2009). Prior to testing and tumour induction, mice were
habituated to the experimental setup in at least two separate sessions.
Mechanical sensitivity was represented as frequency of response,
calculated as a percentage over ﬁve subsequent stimulations. Data are
shown for some representative ﬁlaments, e.g. 0.07 or 0.02 g as well as
in the form of area under the curve (AUC) calculated considering mean
responses to all ﬁlament strengths from 0.02 to 1.0 g. Mechanical
response threshold was calculated as von Frey ﬁlament strength
required to achieve 50% (80% for Fig 3, panel B and Fig 6, panel F)
withdrawal frequency. The experimentator was fully blinded to the
identity of the treatment in all behavioural tests.
RNA isolation
For gaining RNA in the context of microarray and qRT‐PCR experi-
ments, L3, L4 and L5 DRGs from tumour‐bearing (described above) or
control mice were pooled from four mice into one biological sample. All
experiments were performed on triplicate biological samples. RNA
isolation was carried out usingmirVana™miRNA Isolation Kit (Ambion,
AM 1561) following manufacturer’s instructions to enrich miRNA
fraction and quality control was undertaken as described in details in
Supporting Information Methods. Two hundred nanograms of total
RNA from each biological sample was used as starting material for
miRNA expression analysis.
miRNA expression proﬁling and data analysis
Illumina Mouse Sentrix‐6 beadchip arrays were used for miRNA
expression arrays. Polyadenylation, 1st strand cDNA synthesis,
hybridization of miRNA‐speciﬁc oligos to the immobilized ﬁrst strand
cDNA, miRNA‐speciﬁc second strand synthesis, universal PCR
ampliﬁcation and hybridization to the array were performed at the
Genomic and Proteomics core facility, German Cancer Research Center,
Heidelberg following in‐house stringent quality control criteria. The
array intensity data were imported into Beadstudio version 3.0
(Illumina), a software package that permits visualization and
normalization of the data. We used the quantile normalization
method (Chudin et al, 2006) for all the analyses reported here. To
shortlist subset miRs regulated consistently in terms of biological
and technical stability with more stringency for further analysis, we
considered those miRNAs for which the distance between mean
expression values between tumour‐bearing and sham mice was at
least ﬁve times greater than the sum of standard deviation of two
groups. In analogical calculations, this value roughly equals to
p<0.001 (two tailed t‐test assuming equal variances).
As the expression array was performed based onmiRBase version 12
and owing to frequent dynamic changes in this online repository, all
miRNA identiﬁers were updated according to current version of
miRBase (version 19). However, to maintain the continuity of data
representation and future reference purposes, sequences and accession
numbers of 57 subset of signiﬁcantly regulated miRNAs are provided in
Supporting Information Table S1.
PCR ampliﬁcation of miRNAs and mRNAs
For the generation of miRNA‐speciﬁc ﬁrst strand cDNA, 20ng of total
RNA was reverse transcribed by miRNA speciﬁc RT primer using
TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems,
4366597) followingmanufacturer’s instructions.Twenty nanograms ofEMBO Mol Med (2013) 5, 1740–1758 total RNA was used to prepare the cDNA using random primers from
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
4368814) following manufacturer’s instructions for mRNA ampliﬁca-
tion. Four microlitres of prepared cDNA was PCR ampliﬁed in each
reaction using corresponding miRNA‐ or mRNA‐speciﬁc primers using
TaqMan® Universal Master Mix II, (Applied Biosystems, 4440040)
following manufacturer’s instructions on Chromo 4 detection system
(BioRad, USA). The expression level of the target miRNA was normalized
to expression of small nucleolar RNA 202 (sno202) and that of target
mRNA was normalized to the expression of GAPDH. Each miRNA or
mRNA was ampliﬁed in triplicates and Ct values were recorded. Fold
change in the miRNA or mRNA expression in tumour bearing DRG
samples over corresponding Sham samples in triplicate samples was
calculated using DDCT method (Fu et al, 2006), which measures
relative change in expression of a miRNA (or gene) from treatment to
control compared to the reference small RNA (or gene). All miRNA and
mRNA assays were purchased from Applied Biosystems and Assay IDs
are as following: snoRNA202: 001232, miR‐1: 002222, miR‐34c‐5p:
000428, miR‐544‐3p: 002550, miR‐370‐3p: 002275, miR‐483:
002560, miR‐291b‐5p: 002537; GAPDH: 4352932E; Clcn3:
Mm01348786_m1.
miRNA inhibitors and modiﬁed mimics
LNA based in vivo inhibitors for miR‐1a‐3p, 34c‐5p and 544‐3p and
respective mismatch controls with several mismatches were custom
ordered from Exiqon (Denmark). Sequences of inhibitor and mismatch
inhibitors are given in the Supporting Information Table S2. miRIDIAN
microRNA mimics for mmu‐miR‐370‐3p (C‐310619‐07), miR‐483
(C‐310641‐07) and miR‐291b‐5p (C‐310666‐03) were further
custom‐modiﬁed with 30‐cholesterol conjugation on passenger strand
and 30‐FITC conjugation on guide strand to facilitate the in vivo uptake
and facilitate visualization, respectively. Both inhibitors and mimics
were synthesized from ribo‐nucleotides and their functional efﬁcacy
in vivowas tested.ThesemodiﬁedmiRNA‐mimics were custom ordered
from Thermoﬁscher Scientiﬁc Molecular biology (formerly Dharmacon,
USA). Both mimics and inhibitors were puriﬁed via HPLC and
lyophilized powder was reconstituted in 1 PBS at pH 7.4 at a
concentration of 500pmoles/ml, made into aliquots of working
volumes and frozen at 20°C to avoid freeze–thaw cycles.
Intrathecal application of miRNA/mRNA modulators in vivo
Mimic or inhibitor for each miRNA was applied intrathecally via
subdurally implanted chronic catheters as we have described
previously (Luo et al, 2012). On the day of application, inhibitors or
mismatch inhibitors were mixed with 4ml of i‐Fect™ in vivo
transfection reagent (Neuromics, Edina, MN) to a ﬁnal concentration
of 10 pmol/5ml; injections were performed every 24h over 5
consequent days starting on Day 4 after tumour implantation (PID‐
4 to PID‐9). Lyophilized miRNA‐mimics were reconstituted at a ﬁnal
concentration of 400 pmol/ml in 1 PBS at pH 7.4 and injected every
24 h over 7 consequent days from Day 0 to PID‐7. Each injection of
inhibitor or mimic was followed by a 5ml saline ﬂush. At the end of
each experiment, catheter placement was evaluated via laminectomy
and the data were only used from those mice, which showed correct
catheter placement.
For Clcn3 knock‐down in DRGs, a set of three MISSION‐predesigned
siRNAs, which target the coding sequence of Clcn3mRNA (PDSIRNA5H‐2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1755
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PROBLEM:
Various forms of cancer are associated with debilitating pain.
Approximately one-third of adults who are actively receiving
treatment for cancer and two-thirds of those with advanced
malignant disease experience pain. Various types of carcinomas
and sarcomas metastasize to skeletal bones and cause
spontaneous bone pain, hyperalgesia (exaggerated pain) and
allodynia (pain in response to a normally innocuous stimulus),
which is accompanied by bone degradation and remodelling of
peripheral nerves. Cancer-mediated pain has both neuropathic
and inflammatory components associated with it and it is
difficult to treat the cancer-associated pain in a large number of
clinical cases, particularly the neuropathic component involved.
Current available therapeutics option or their application are
severely limited owing to the widespread side effects. In order to
develop novel, mechanism-based therapeutic strategies, it is
imperative to delineate the cellular and molecular mechanisms
underlying cancer-induced pain. miRNAs, a type of small non-
coding RNAs in the genome, have recently been shown to be
important for themediation of various pathological conditions. A
unique feature of miRNAs is that they act as ‘master switches’ in
the genome by regulating many proteins at the same time,
harbouring an enormous potential to be used as therapeutic
targets. In the current study, we attempted to identify unique
microRNA signatures and their mode of action associated with
the cancer-mediated pain conditions by utilizing a clinically
relevant model of metastatic bone-cancer pain in mice.
RESULTS:
We identified tumour-induced conditions are associated with a
marked dysregulation of 57 miRNAs in peripheral sensory
neurons, which relay the pain signals from the corresponding
tumour-affected areas to the spinal cord and brain. We
established effective protocols to target individual miRNAs
specifically in the sensory neurons in vivo to test the
importance of these deregulated miRNAs in the mediation of
tumour-associated pain. Following our protocol, we identified
three miRNAs namely miR-1a-3p, miR-34c-5p and miR-370-3p
to be enhancing tumour-pain and miR-483-3p to counteract
it. Our results indicate that reversing cancer-mediated over-
expression of miR-1a-3p or miR-34c-5p or reversing tumour-
mediated downregulation of miR-483-3p in the sensory
neurons reduces tumour-associated pain. Furthermore, our
detailed analyses identified the chloride channel 3 (Clcn3) as a
target of miR-1a-3p in sensory neurons and functionally
validated Clcn3 as a novel pain modulator acting in the
periphery.
IMPACT:
Our results of this study deliver valuable new insights
into mechanisms of cancer pain and open up very attractive
therapeutic options. This is particularly relevant since
ncRNA-based diagnostics and therapeutics may have superior
advantages by targeting multiple pain-associated genes
simultaneously, and this study provides a preclinical basis in
the context of cancer-associated pain. Our results
underscore the importance of microRNA regulation in
sensory neurons in the context of bone metastatic pain and
systematically delineate the potential of ncRNAs as
druggable targets for future treatment of cancer-associated
pain.
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1756HA04065459, ‐HA04065461 and ‐HA04065463) or Universal siRNA
negative control (8013156981) were purchased from Sigma–Aldrich
Chemie GmbH (Germany). Intrathecal injections were performed
every 24h over 9 consequent days starting Day 0 until PID‐8 after
tumour implantation at a ﬁnal concentration of 1.2mg/ml per
injection. The same methodology and scheme explained above for
miRNA‐inhibitors was used. For conﬁrming siRNA‐mediated knock‐
down of Clcn3, L3, L4, L5 DRGs were collected 48h after a single
injection of Clcn3‐ or control‐siRNA and analysed for Clcn3 expression
by qRT‐PCR.
miRNA targets validation
Target prediction analysis was performed by comprehensively employ-
ing 14 state‐of‐art algorithms (see Supporting Information Table S3
and Supporting Information Methods for detailed list). Targets
commonly predicted by at least 2 out of these 14 algorithms were
analysed via quantitative RT‐PCR using NanoString‐nCounter™ based
gene quantiﬁcation method to validate microarray expression data.
Probes speciﬁcally targeting desired gene of interest were ordered from 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.the Nanostring Technologies (USA) who designed, synthesized and
delivered the probes to the nCounter core facility at the Institute of
human genetics, University clinic, Heidelberg, Germany. Two hundred
nanograms of total RNA was used to analyse the target genes
expression together with ﬁve housekeeping genes namely clathrin,
heavy polypeptide (Cltc), glyceraldehyde‐3‐phosphate dehydrogenase
(Gapdh), glucuronidase beta (Gusb), hypoxanthine guanine phosphor-
ibosyl transferase (Hprt) and tubulin, beta 5 class I (Tubb5). Expression
of target genes was analysed by comparing treated and control
samples using normalized expression values.
Data analysis and statistics
All data are expressed as mean standard error of the mean (SEM).
Two‐way repeated measures ANOVA followed by Bonferroni post hoc
test was used to assess statistical signiﬁcance in behavioural
experiments. ANOVA followed by post hoc Fischer’s test was used to
assess statistical signiﬁcance in QRT‐PCR experiments. Student’s t‐test
was used to assess statistical signiﬁcance in reporter assays. Changes
with p0.05 were considered to be statistically signiﬁcant.EMBO Mol Med (2013) 5, 1740–1758
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